Reata Pharmaceuticals Inc Stock

Description Reata Pharms

Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is a publicly traded biopharmaceutical company founded in 2002 and based in Plano, Texas. The company is primarily focused on developing innovative therapies for patients with life-threatening and serious diseases, mainly in the areas of cardiovascular, metabolic, and neurological disorders.

Reata Pharmaceuticals specializes in utilizing its understanding of transcription factors, which are proteins that regulate gene expression, to create molecules that selectively target important pathways involved in the processes of disease. Some of the leading product candidates in their pipeline include:

1. Bardoxolone methyl – This is an investigational, once-daily, orally administered activator of Nrf2 (a transcription factor that regulates antioxidant and other defense mechanisms). The drug is being developed for the treatment of chronic kidney disease caused by Alport syndrome and autoimmune nephropathies, as well as connective tissue disease-associated pulmonary arterial hypertension.

2. Omaveloxolone – This is another investigational, orally administered Nrf2 activator that is being studied for the treatment of Friedreich's ataxia, a (rare and debilitating neuro-muscular disorder) and other mitochondrial diseases.

Reata Pharmaceuticals is also exploring the use of its candidate compounds in other indications such as obesity, diabetes, mitochondrial myopathies, and cancer.

The company's stock is listed on the NASDAQ Stock Market under the ticker symbol "RETA." Investors interested in Reata Pharmaceuticals should closely monitor the progress of the company's clinical trials, partnerships, and regulatory approval processes, as these factors can significantly impact the company’s stock price and future growth prospects.